plus the same contraceptive for a mean duration of 17 months, and they were randomized for discontinuation of Met or not. Fasting blood glucose, serum insulin, testosterone, lipid profile, adiponectin, and IL-6 were determined at the start and after 3 months, together with body composition, by dual energy x-ray absorptiometry.
The results of studies A and B complemented each other; the addition of Met was found to have consistently (more) normalizing effects on IL-6 and adiponectin, on lean mass (mean Met benefit of ؉1.2 kg in study A and ؉0.6 kg in study B), and in particular on abdominal fat excess [Met benefit of ؊0.7 kg (A) and ؊0.3 kg (B)].
In conclusion, Met proved to be a pivotal component of a prime combination therapy that attenuates the dysadipocytokinemia, the lean mass deficit, and the central adiposity of young patients with polycystic ovary syndrome. (J Clin Endocrinol Metab 90: 39 -43, 2005) P OLYCYSTIC OVARY SYNDROME (PCOS), a variable constellation of anovulatory hyperandrogenism with hyperinsulinemia and/or dyslipidemia, is the most frequent endocrine disorder of young women (1) (2) (3) . One of the physical stigmata of women with PCOS, even if nonobese, is an excess of central fat and a deficit of lean mass, both of which seem to be reflections of the prolonged dysadipocytokinemia that accompanies hyperinsulinemic hyperandrogenism and that is aggravated by monotherapy with an oral estroprogestagen contraceptive (OC) even with an OC containing drospirenone (4 -8) .
At present, there is no approved therapy for PCOS. Low-dose flutamide (Flu)-metformin (Met) plus ethinylestradiol-drospirenone was recently found to reduce total and abdominal fat excess, to diminish the deficit in lean mass, and to attenuate the dysadipocytokinemia (as judged by IL-6 and adiponectin) in young and nonobese women with PCOS (8 -10) . The development of this combination therapy departed from the evidence that Flu and Met exert additively beneficial effects on endocrinemetabolic indices (11) and that, together, they are capable of correcting the dysadipocytokinemia and the adiposity of young PCOS patients (5, 6, 8, 9) . Although there is emerging consensus about the need for insulin sensitization at the start of PCOS treatment (12) (13) (14) (15) (16) , the additive benefits of Met remain to be shown in the copresence of Flu and an OC, as well in the initiation phase as after prolonged intake of such combination therapy.
In two randomized pilot studies (A and B), we assessed the additive effects of Met in young PCOS patients (A) at the start of Flu and a drospirenone-containing OC, and (B) after more than 1 yr on Flu-Met plus the same OC. Gallwey score above 8); and high serum androstenedione, total testosterone, or free androgen index (testosterone ϫ 100/SHBG); and a 17-hydroxyprogesterone hyperresponse (Ͼ160 ng/dl) to GnRH agonist (leuprolide acetate, Procrin, Abbott, Madrid, Spain, 500 g sc).
Subjects and Methods

Study population
Before study start, none of the patients were receiving a contraceptive or another medication known to affect gonadal or adrenal function, or carbohydrate or lipid metabolism. Studies A and B. Exclusion criteria were: a BMI Ն 26 kg/m 2 ; evidence of thyroid dysfunction, Cushing's syndrome, hyperprolactinemia; glucose intolerance (17) ; family or personal history of diabetes mellitus; lateonset congenital adrenal hyperplasia (18, 19) ; abnormal blood count or serum electrolytes; abnormal screening results for liver and kidney function.
The studies were conducted in Barcelona, after approval by the Institutional Review Board of Sant Joan University Hospital; informed consent was obtained from the patients and/or their parents, with assent from minors. None of the results in the present studies have been reported previously.
Study design
Both studies were open labeled; treatment subgroups were assembled by randomization (1:1 ratio; Gran Mos program, Medical Research Institute of Barcelona) (5, 8, 9) .
FIG. 1.
Changes over 3 months in lean body mass, body fat mass, and abdominal fat mass in 31 young patients (age ϳ16 yr) with hyperinsulinemic ovarian hyperandrogenism. All participants started on Flu and an OC [ethinylestradiol (EE) ϩ drospirenone], and they were randomized to receive Met (850 mg/d) in addition (•, Met ϩ, n ϭ 16) or not (E, Met -, n ϭ 15). The addition of Met was found to increase lean mass and to reduce total and abdominal fat excess, without changing body weight (see Table 1 for values). 
Endocrine-metabolic assessment
Fasting blood glucose, serum insulin, lipid profile, SHBG, testosterone, androstenedione, dehydroepiandrosterone sulfate (DHEAS), adiponectin, and IL-6 were determined at baseline and after 3 months, together with indices of hepatic and renal function, as additional safety variables.
Body composition, assays, and statistics
Body composition was assessed by dual-energy x-ray absorptiometry at study start and after 3 months, with a Lunar Prodigy coupled to Lunar software (version 3.4/3.5, Lunar Corp., Madison, WI) (20) . Absolute (kilograms) whole-body fat and lean mass were assessed, as well as fat content in the abdominal region, which was defined as the area between the dome of the diaphragm (cephalad limit) and the top of the great throcanter (caudal limit) (21) . Total irradiation dose per assessment was 0.1 mSievert. Coefficients of variation (CVs) for scanning precision were 2.0% and 2.6% for fat and lean body mass (22) ; intraindividual CV for abdominal fat mass was 0.7%.
Serum glucose was measured by the glucose oxidase method. Immunoreactive insulin was assayed by IMX (Abbott, Santa Clara, CA); intra-and interassay CVs were 4.7% and 7.2%. Serum testosterone, androstenedione, DHEAS, 17-hydroxyprogesterone, and SHBG were assayed as described (5, 8) . IL-6 was measured by immunochemiluminescence (Immulite 2000, Diagnostic Products, Los Angeles, CA), with a detection limit of 100 fg/ml; intra-and interassay CVs were 3.5% and 5.1% (8, 9). Adiponectin was measured by RIA (Linco Research, St.
Charles, MO); intra-and interassay CVs were 6.2% and 6.9% (8, 9) . Samples were stored at Ϫ20 C until assay.
For uniformity, results are expressed as mean Ϯ sem. Two-sided t tests (paired or unpaired, as appropriate) were used for statistical comparisons between subgroups; per variable, only one comparison was performed; significance level was set at P Ͻ 0.05. Table 1 and Fig. 1 summarize the main findings. At the start, the study population was characterized by hyperandrogenism, dysadipocytokinemia, and central adiposity; five of 31 patients had regular menses (cycles of 25-35 d), and 26 were oligo-or amenorrheic. Patients receiving Flu plus OC experienced decreases in testosterone, androstenedione, DHEAS, and low-density lipoprotein (LDL) cholesterol, as well as increments in SHBG, adiponectin, and high-density lipoprotein (HDL) cholesterol, irrespective of whether Met was added. By comparison of 3-mo changes between subgroups, however, the addition of Met was found to have consistently beneficial effects on IL-6 and body adiposity, whereas body weight remained unchanged. Two adolescents experienced spotting without breakthrough bleeding at the beginning of the first or second cycle on OC. Each treatment was well tolerated; indices of hepatic and renal function remained unchanged. Table 2 summarizes the main findings. After more than 1 yr on Flu-Met plus OC, changes were still ongoing (SHBG, DHEAS, adiponectin, lean mass). Comparison of 3-mo changes between subgroups disclosed that maintenance of Met addition still had detectably beneficial effects on circulating IL-6 and adiponectin, as well as on body adiposity. Treatments were well tolerated; indices of hepatic and renal function remained stable.
Results
Study A
Study B
.7 Ϯ 0.2 Testosterone (ng/dl) 59 Ϯ 6 5 7 Ϯ 6 6 7 Ϯ 8 4 8 Ϯ 4 d Ϫ2 Ϯ 7 Ϫ19 Ϯ 6 Androstenedione (ng/dl) 217 Ϯ 18 215 Ϯ 17 189 Ϯ 13 194 Ϯ 14 Ϫ2 Ϯ 8 5 Ϯ 7 DHEAS (g/dl) 188 Ϯ 17 182 Ϯ 16 178 Ϯ 16 159 Ϯ 14 c Ϫ7 Ϯ 11 Ϫ19 Ϯ 8 LDL cholesterol (mg/dl) 95 Ϯ 6 9 7 Ϯ 5 9 1 Ϯ 6 8 6 Ϯ 5 2 Ϯ 4 Ϫ5 Ϯ 5 HDL cholesterol (mg/dl) 73 Ϯ 4 7 8 Ϯ 4 c 74 Ϯ 2 7 8 Ϯ 4 5 Ϯ 2 4 Ϯ 4 Triglycerides (mg/dl) 86 Ϯ 8 8 4 Ϯ 7 8 9 Ϯ 9 8 8 Ϯ 7 Ϫ2 Ϯ 9 Ϫ1 Ϯ 7 IL-6 (fg/ml) 757 Ϯ 65 834 Ϯ 61 880 Ϯ 117 735 Ϯ 67 77 Ϯ 47 Ϫ145 Ϯ 104
Discussion
In a young PCOS population, we compared the efficacy of Flu plus ethinylestradiol-drospirenone to that of the same duo plus Met. Efficacy was not only judged by classic markers such as BMI, fasting glucose/insulin and lipids, testosterone, and SHBG, but also by indices related to atherogenesis, such as proinflammatory IL-6, antiinflammatory adiponectin, and central adiposity (8, 9, (23) (24) (25) (26) (27) . The compared therapies were found to yield similar results for the classic markers but different or opposite outcomes for the new indices, including for lean mass and for abdominal fat excess; each of the latter outcomes was to the advantage of adding Met. The use of indices such as adipocytokines and body adiposity thus allowed us to unmask the fact that the addition of Met to Flu-OC therapy confers lipolytic and possibly antiatherogenic benefits. These findings corroborate Met as an adjuvans in the long-term prevention of the cardiovascular and metabolic disorders that are linked to PCOS (28 -30) .
When given in monotherapy to nonobese adolescents or young women with PCOS, Met lowers high testosterone levels, attenuates the low-grade inflammatory state (as judged by circulating C-reactive protein, IL-6, and/or adiponectin), and reduces central adiposity; in monotherapy, Met remains effective for at least 1 yr, and its discontinuation elicits a rapid return to pretreatment conditions (31-35). When given together with Flu, Met is also known to be effective for at least 9 months; discontinuation of such dual therapy is also followed by a swift reversal of treatment benefits (5, 8) . When given together with both Flu and a drospirenone-containing OC, Met now proved to still have detectably lipolytic and possibly antiatherogenic effects both at the start and after more than 1 yr of such a triple therapy.
In conclusion, Met proved to be a pivotal component of a prime combination therapy that attenuates the dysadipocytokinemia, the lean mass deficit, and the central adiposity of young patients with PCOS. JCEM is published monthly by The Endocrine Society (http://www.endo-society.org), the foremost professional society serving the endocrine community.
